Cargando…
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts
SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedo...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499676/ https://www.ncbi.nlm.nih.gov/pubmed/32906151 http://dx.doi.org/10.1093/infdis/jiaa579 |
| _version_ | 1783583730950995968 |
|---|---|
| author | Naranbhai, Vivek Chang, Christina C Beltran, Wilfredo F Garcia Miller, Tyler E Astudillo, Michael G Villalba, Julian A Yang, Diane Gelfand, Jeffrey Bernstein, Bradley E Feldman, Jared Hauser, Blake M Caradonna, Timothy M Alter, Galit Murali, Mandakolathur R Jasrasaria, Rashmi Quinlan, Joan Xerras, Dean C Betancourt, Joseph R Louis, David N Schmidt, Aaron G Lennerz, Jochen Poznansky, Mark C Iafrate, A John |
| author_facet | Naranbhai, Vivek Chang, Christina C Beltran, Wilfredo F Garcia Miller, Tyler E Astudillo, Michael G Villalba, Julian A Yang, Diane Gelfand, Jeffrey Bernstein, Bradley E Feldman, Jared Hauser, Blake M Caradonna, Timothy M Alter, Galit Murali, Mandakolathur R Jasrasaria, Rashmi Quinlan, Joan Xerras, Dean C Betancourt, Joseph R Louis, David N Schmidt, Aaron G Lennerz, Jochen Poznansky, Mark C Iafrate, A John |
| author_sort | Naranbhai, Vivek |
| collection | PubMed |
| description | SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM(+)IgG(+), 9.0% IgM(+)IgG(−), and 5.0% IgM(−)IgG(+)). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM(+)IgG(−). These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection. |
| format | Online Article Text |
| id | pubmed-7499676 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74996762020-09-21 High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts Naranbhai, Vivek Chang, Christina C Beltran, Wilfredo F Garcia Miller, Tyler E Astudillo, Michael G Villalba, Julian A Yang, Diane Gelfand, Jeffrey Bernstein, Bradley E Feldman, Jared Hauser, Blake M Caradonna, Timothy M Alter, Galit Murali, Mandakolathur R Jasrasaria, Rashmi Quinlan, Joan Xerras, Dean C Betancourt, Joseph R Louis, David N Schmidt, Aaron G Lennerz, Jochen Poznansky, Mark C Iafrate, A John J Infect Dis Major Articles and Brief Reports SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM(+)IgG(+), 9.0% IgM(+)IgG(−), and 5.0% IgM(−)IgG(+)). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM(+)IgG(−). These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection. Oxford University Press 2020-09-09 /pmc/articles/PMC7499676/ /pubmed/32906151 http://dx.doi.org/10.1093/infdis/jiaa579 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
| spellingShingle | Major Articles and Brief Reports Naranbhai, Vivek Chang, Christina C Beltran, Wilfredo F Garcia Miller, Tyler E Astudillo, Michael G Villalba, Julian A Yang, Diane Gelfand, Jeffrey Bernstein, Bradley E Feldman, Jared Hauser, Blake M Caradonna, Timothy M Alter, Galit Murali, Mandakolathur R Jasrasaria, Rashmi Quinlan, Joan Xerras, Dean C Betancourt, Joseph R Louis, David N Schmidt, Aaron G Lennerz, Jochen Poznansky, Mark C Iafrate, A John High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title | High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title_full | High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title_fullStr | High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title_full_unstemmed | High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title_short | High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| title_sort | high seroprevalence of anti-sars-cov-2 antibodies in chelsea, massachusetts |
| topic | Major Articles and Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499676/ https://www.ncbi.nlm.nih.gov/pubmed/32906151 http://dx.doi.org/10.1093/infdis/jiaa579 |
| work_keys_str_mv | AT naranbhaivivek highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT changchristinac highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT beltranwilfredofgarcia highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT millertylere highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT astudillomichaelg highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT villalbajuliana highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT yangdiane highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT gelfandjeffrey highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT bernsteinbradleye highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT feldmanjared highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT hauserblakem highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT caradonnatimothym highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT altergalit highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT muralimandakolathurr highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT jasrasariarashmi highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT quinlanjoan highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT xerrasdeanc highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT betancourtjosephr highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT louisdavidn highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT schmidtaarong highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT lennerzjochen highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT poznanskymarkc highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts AT iafrateajohn highseroprevalenceofantisarscov2antibodiesinchelseamassachusetts |